23 # Corresponding author:

24 Prof Gengfu Xiao: State Key Laboratory of Virology, Wuhan Institute of Virology,

25 Chinese Academy of Sciences, 44 Xiaohongshan Road, Wuchang District, Wuhan,

26 Hubei 430071, China. E-mail: xiaogf@wh.iov.cn

27 Prof Ke Peng: State Key Laboratory of Virology, Wuhan Institute of Virology,

28 Chinese Academy of Sciences, 44 Xiaohongshan Road, Wuchang District, Wuhan,

29 Hubei 430071, China. E-mail: pengke@wh.iov.cn

30 Prof Hao Li: Beijing Institute of Microbiology and Epidemiology, State Key

31 Laboratory of Pathogen and Biosecurity, Beijing 100071, P. R. China. E-mail:

32 lihao_1986@126.com

33 **Abstract**

34 The coronavirus disease (COVID-19) caused by the novel severe acute respiratory
35 syndrome coronavirus 2 (SARS-CoV-2) has now spread to more than 100 countries
36 posing as a serious threat to the public health on a global scale. Patients with
37 comorbidity such as hypertension suffer more severe infection with elevated case
38 fatality rate. Development of effective anti-viral drug is in urgent need to treat
39 COVID-19 patients. Here we report that calcium channel blockers (CCBs), a type of
40 anti-hypertension drugs that are widely used in the clinics, can significantly inhibit the
41 post-entry replication events of SARS-CoV-2 in vitro. Comparison with two other
42 major types of anti-hypertension drugs, the angiotensin converting enzyme inhibitors
43 (ACEI) and angiotensin II receptor blockers (ARB), showed that only CCBs display
44 significant anti-SARS-CoV-2 efficacy. Combined treatment with chloroquine and
45 CCBs significantly enhanced the anti-SARS-CoV-2 efficacy. Retrospective clinical
46 investigation of COVID-19 patients revealed that the CCB amlodipine besylate
47 administration was associated with reduced case fatality rate of patients with
48 hypertension. Results from this study suggest that CCB administration for COVID-19
49 patients with hypertension as the comorbidity might improve the disease outcome.

50

51 **Keywords**

52 SARS-CoV-2, COVID-19, hypertension, calcium channel blockers, retrospective
53 clinical investigation

54 **Introduction**

55 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative
 56 pathogen of the novel coronavirus disease (COVID-19) that recently occurred in
 57 Wuhan, China in late December 2019 (1, 2). SARS-CoV-2 infection induced similar
 58 symptoms with SARS-CoV including fever, cough, dyspnea, etc and can result in
 59 multiple organ dysfunction syndrome and death in severe cases (3). The virus has
 60 caused a global pandemic transmission posing as a serious threat to the public health.
 61 As of Mar 19, 2020, there are over 203,000 confirmed COVID-19 cases with more
 62 than 8,100 deaths from SARS-CoV-2 infection around the world. Due to its high
 63 transmissibility and severe infection outcome, the World Health Organization has
 64 declared the SARS-CoV-2 a public health emergency of international concern. The
 65 rapid transmission of SARS-CoV-2 raises the concern whether it will become a
 66 seasonal coronavirus like hCoV-229E, OC43, NL63, and HKU1, however with a
 67 much higher mortality rate. Development of effective anti-viral drugs is urgently
 68 needed to contain the current transmission of SARS-CoV-2 and to counteract its
 69 potential re-emergence in the future.

70

71 So far, no antiviral drug for SARS-CoV-2 has been officially proved to be effective in
 72 treating COVID-19 patients. Compared with de-novo drug development, which
 73 normally takes years of development and evaluation, repurposing preexisting drugs
 74 that are in clinical use to treat virus infection is one of the most effective strategies for
 75 developing drug against emerging viruses (4). Our recent study has reported that

76 remdesivir, favipiravir and chloroquine (CQ) have distinct anti-SARS-CoV-2 effect in
 77 vitro (5). Remdesivir was first developed for treating Ebola virus (6), and showed
 78 strong anti-SARS-CoV and MERS-CoV activity in vitro (7) and in mouse model (8). A
 79 randomized controlled trial has been initiated to assess the efficacy and safety of
 80 remdesivir to treat COVID-19 and the result is expected to be released in April (4).
 81 Favipiravir is an approved anti-influenza drug for clinical use in Japan and very
 82 recently in China. Similar with remdesivir, favipiravir has also been registered in
 83 clinical trial to evaluate its efficacy in treating COVID-19 (4). CQ is an anti-malaria
 84 drug that has been developed in the 1940's with a safe record in clinical
 85 administration (9). Given its approved status it was quickly tested in clinics and a
 86 recent study reported its potential benefits in treating COVID-19 patients (10). These
 87 progresses strongly support the endeavor of repurposing approved drugs for
 88 COVID-19 treatment.

89
 90 The most affected COVID-19 patients are the elderly who often have comorbidities
 91 such as hypertension, diabetes, cardiovascular disease, etc (11). These patients suffer
 92 more severe infection outcome with significantly higher case fatality rate (11). The
 93 current therapeutic regime is largely symptomatic treatment and specific evaluation of
 94 drug treatment for COVID-19 patients with different comorbidities is still lacking.
 95 Identification of more drug candidates with anti-SARS-CoV-2 efficacy would help to
 96 provide more options from which safe and effective drugs can be selected and/or
 97 combined for personalized medication for the patients on an individual level.

98

99 Calcium channel blockers (CCBs) are widely used in the clinics for treating
 100 hypertension, angina pectoris, supraventricular arrhythmias (12). Recently, CCBs
 101 were also reported to have anti-viral effect against several emerging viruses including
 102 bunyaviruses, arenaviruses and flaviviruses (13-15). About 30% of SARS-CoV-2
 103 patients have hypertension as comorbidity and these patients suffer the case fatality
 104 rate of up to 14% (11, 16) urging that effective drug treatment for these patients needs
 105 to be evaluated. Recently, a concern was raised about whether administration of
 106 anti-hypertension drugs of ARB or ACEI to COVID-19 patients would worsen the
 107 disease progression through up-regulation of ACE2 expression level and result in
 108 more severe SARS-CoV-2 infection (22). In this study we tested a panel of
 109 anti-hypertension drugs that are in clinical use and found that the CCBs benidipine
 110 HCl and amlodipine besylate have significant anti-viral effect in vitro. Retrospective
 111 clinical investigation showed that amlodipine besylate was associated with reduced
 112 case fatality rate of COVID-19 patients with hypertension. These results provide
 113 valuable reference for selecting drug treatment for COVID-19 patients with
 114 hypertension as the underlying comorbidity.

115 **Results:**

116 **CCBs inhibit SARS-CoV-2 infection in vitro.**

117 To test whether CCBs can inhibit SARS-CoV-2 replication, Vero E6 cells were treated
 118 with a panel of 9 clinically approved CCBs, and then infected with SARS-CoV-2 at a
 119 multiplicity of infection (MOI) of 0.05. At 24 hours post infection (p.i.), copy
 120 numbers of viral RNA in the supernatant were measured with qRT-PCR (Figure 1A),
 121 and the intracellular level of virus infection was monitored by immunofluorescence
 122 with an antibody against virus NP protein (Figure 1B). We found that four CCBs,
 123 benidipine HCl, amlodipine besylate, cilnidipine and nicardipine HCl, significantly
 124 inhibited SARS-CoV-2 replication (Figure 1). Experiments with serial concentrations
 125 of drug treatment revealed that these four CCBs inhibited SARS-CoV-2 replication in
 126 a dose-dependent manner, without causing strong cytotoxic effect (Figure 2A). The
 127 half maximal inhibitory concentrations (IC_{50}) of benidipine HCl, amlodipine besylate,
 128 cilnidipine, nicardipine HCl were 3.81, 4.17, 11.58 and 13.32 μ M, respectively, and
 129 the half cytotoxic concentration (CC_{50}) of all four drugs were calculated to be above
 130 100 μ M. The drug selection index (SI) of these four CCBs was calculated to be >
 131 26.25, > 23.98, >8.64 and >7.51, respectively (Figure 2A). Similar inhibition effects
 132 of these four CCBs were also observed on the human hepatocyte cell line Huh7
 133 (Supplementary Figure S1).

134

135 Since CCBs block intracellular calcium influx, we analyzed whether the

136 anti-SARS-CoV-2 effect of CCBs is related with reduced intracellular calcium level.

137 Intracellular calcium level can be reduced through treatment with calcium chelator
138 1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl
139 ester) (BAPTA-AM) or 2-Aminoethyl Diphenylborinate (2APB), a membrane
140 permeable blocker of the inositol 1,4,5-trisphosphate (IP3)-induced Ca^{2+} release (17).
141 Vero E6 cells were treated with serial concentrations of BAPTA-AM or 2APB, and
142 then infected with SARS-CoV-2. At 24 hours p.i., copy numbers of viral RNA in the
143 supernatant were measured with qRT-PCR. As shown in figure 2B, addition of
144 BAPTA-AM or 2APB also significantly inhibited virus replication in a concentration
145 dependent manner, confirming the dependence role of intracellular Ca^{2+} for
146 SARS-CoV-2 replication.

147

148 **CCB inhibits viral replication at the post-entry stage.**

149 To define the event of virus infection that was inhibited by CCBs, time-of-addition
150 assay of drug treatment was performed. The CCB benidipine HCl was chosen for
151 further analysis as it has the lowest effective concentration and the highest SI index of
152 the 4 tested CCBs. Benidipine HCl or 2ABP were added during virus entry, 2-hours
153 post virus infection or through-out virus infection (Figure 3A). The virus production
154 in the supernatant was measured with qRT-PCR and the intracellular NP expression
155 level was determined with western blot and immunofluorescence analysis with the NP
156 antibody. As shown in figure 3B-D, addition of drug through-out virus infection or
157 2-hours after virus entry strongly inhibited virus production, while addition of drug
158 during virus entry did not inhibit virus replication. Notably, compared with drug

159 treatment throughout virus infection, addition of drugs 2-hours after virus entry had
160 slightly lower inhibition efficacy (Figure 3 B,C). Whether this is due to rapid onset of
161 virus replication within the first 2-hours that was not fully blocked by following drug
162 treatment still needs further characterization. Nevertheless, these results indicate that
163 benidipine HCl and 2ABP mainly inhibit virus infection at a stage after virus entry,
164 potentially during virus genome replication/transcription.

165

166 **CCBs but not ARBs or ACEIs display inhibitory effect against SARS-CoV-2**
167 **replication.**

168 Angiotensin II receptor blockers (ARB), angiotensin converting enzyme inhibitors
169 (ACEI) and CCBs represent three major types of anti-hypertension drugs that are in
170 clinical use (18). We next analyzed whether the ARB and ACEI anti-hypertension
171 drugs can also inhibit SARS-CoV-2 replication. Representative ARBs (losartan
172 potassium, valsartan) or ACEIs (enalaprilat dihydrate, enalapril maleate) that are
173 widely used in the clinics (18) were chosen for the evaluation of potential anti-viral
174 effect. Vero E6 cells were treated with serial concentrations of drug compounds and
175 infected with SARS-CoV-2 at an MOI of 0.05. At 24 hours p.i., viral copy number in
176 the supernatant was measured with qRT-PCR and cell viability was measured with
177 CCK-8 assay. As shown in figure 4, in contrast to the distinct inhibition efficacy
178 against SARS-CoV-2 of CCBs, the selected ARBs or ACEIs did not show any
179 significant inhibition effect. These results suggested that of the three types of
180 anti-hypertension drugs only CCBs have significant anti-SARS-CoV-2 efficacy.

181

182 **Combined application of chloroquine (CQ) with CCB resulted in enhanced**
 183 **anti-SARS-CoV-2 effect.**

184 CQ was recently reported to inhibit the entry stage of SARS-CoV-2 replication (5).
 185 Considering that CCB may inhibit SARS-CoV-2 at the post-entry stage, we analyzed
 186 whether the combined application of CQ and CCB would lead to a more distinct
 187 inhibition effect. CQ and CCB were added separately or in combination to the Vero
 188 E6 cells followed by virus infection with SARS-CoV-2 at the MOI of 0.05. At 24
 189 hours p.i., copy numbers of viral RNA in the supernatant were measured with
 190 qRT-PCR and the intracellular level of virus infection was monitored by
 191 immunofluorescence with the NP antibody. As shown in figure 5, while separate
 192 application of CQ or benidipine HCl resulted in distinct reduction of virus replication,
 193 the combined application of benidipine HCl and CQ further enhanced the
 194 anti-SARS-CoV-2 efficacy ($P < 0.001$).

195

196 **Administration of amlodipine besylate is associated with reduced case fatality**
 197 **rate in COVID-19 patients with hypertension.**

198 In order to evaluate whether CCBs have therapeutic effect in COVID-19 patients, we
 199 retrospectively analyzed the medical record of 487 adult COVID-19 patients with
 200 hypertension, including 225 had been admitted into the Tongji Hospital from January
 201 17 to February 14, , and 262 had been admitted into the Union Hospital from January
 202 10 to March 30, 2020. Of these patients 331 concurrently had other underlying

comorbidities such as diabetes, chronic obstructive pulmonary disease, cerebral infarction, etc, 56 had no information on antihypertensive treatment, and 10 were still in the hospital. The 90 patients, who only had hypertension as the comorbidity and were either discharged from the hospital or deceased, were included for the retrospective analysis. Among these patients 44 received amlodipine besylate, 16 received nifedipine, 4 received other CCBs, 17 received other antihypertensive drugs (including ARBs, ACEIs, β -blockers, and thiazide), and 9 had no anti-hypertension drug treatment. No patient was found receiving benidipine HCl treatment. All the patients who did not receive amlodipine besylate were defined as non-amlodipine besylate treated patients. For amlodipine besylate treated and non-amlodipine besylate treated patients, the median (IQR) age was 67 (59.5-72) and 65 (57-74) years, and the median (IQR) delay from symptom onset to hospital admission was 10 (7-14) and 8.5 (6-13.5) days, respectively. Both of the two variables showed no significant inter-group difference. The female proportion was lower in amlodipine besylate treated patients (37.0%) than that (59.1%) in non-amlodipine besylate treated patients, ($P = 0.036$, Supplementary information, Table S1). The frequencies of clinical manifestations that were recorded before or at admission, including fever, cough, feeble, chest distress, shortness of breath, and gastrointestinal symptoms, were comparable between the two groups (all $P > 0.05$, Supplementary information, Table S1). Compared to the non-amlodipine besylate treated group, the amlodipine besylate treated group had lower serum levels of total bilirubin and lactate dehydrogenase ($P = 0.047$ and $P = 0.015$, respectively; Supplementary information, Table S1). All other

laboratory parameters tested at admission were comparable. The commonly prescribed therapies during hospitalization included antibiotics, antiviral agents, traditional Chinese medicines, corticosteroids, and respiratory support. The amlodipine besylate treated group had lower frequency of antibiotics and higher frequency of corticosteroids ($P = 0.028$ and $P = 0.006$, respectively; Supplementary information, Table S2), while other therapies were observed with comparable frequencies between the two groups.

For the primary outcome of mortality, a beneficial effect in reducing the case fatality rate (CFR) was observed in patients receiving amlodipine besylate, with the CFR being significantly decreased from 26.1% (12/46) in non-amlodipine besylate treated group to 6.8% (3/44) in amlodipine besylate treated group ($P = 0.022$). Kaplan-Meier analysis similarly demonstrated reduced risk of death in amlodipine besylate treated group, in comparison with non-amlodipine besylate treated group ($P = 0.033$, log-rank test; Figure 6A). The effect amlodipine besylate treatment of on CFR remained significant with the use of Cox regression model by adjusting for age, sex, the delay from symptom onset to hospital admission, and therapies administration (hazard ratio (HR) 0.182, 95% confidence interval (CI) 0.037-0.897, $P = 0.036$; Table 1). Further analysis showed that the CFRs were higher in all other patient groups, with 12.5% (2/16) in patients receiving nifedipine, 25.0 (1/4) in patients receiving other CCBs, 41.2% (7/17) in patients receiving other anti-hypertension drugs, 22.2% (2/9) in patients without receiving anti-hypertension drugs. When compared to the patients

247 without receiving anti-hypertension drugs, significant treatment effect was only

248 observed in the patients receiving amlodipine besylate (Table 1; Figure 6B).

249 **Discussion :**

250 Depending on the studies, around 13-30% of COVID-19 patients have hypertension
 251 as the underlying comorbidity (11, 16, 19). The case fatality rate of this group of
 252 patient is calculated to be 6%, which is more than 6-fold higher than the CFR of
 253 people without underlying comorbidity (0.9%) (19). In Wuhan, where the proportion
 254 of patients with critical conditions is higher, the CFR of patients with hypertension
 255 can be up to 14%. Effective medication is needed for treatment of this group of
 256 patients. ARBs, ACEIs and CCBs are three major types of anti-hypertension drugs
 257 that are widely used in the clinics. It was reported that the ARBs or ACEIs, such as
 258 losartan, olmesartan, lisinopril, etc, lead to significantly higher cardiac ACE2 mRNA
 259 level in animal model (20, 21). Since the SARS-CoV-2 virus uses ACE2 as its entry
 260 receptor, this raises the concern whether administration of these two types of drugs
 261 would lead to higher expression level of ACE2 and result in more severe virus
 262 infection (22). We showed here that, of the three types of anti-hypertension drugs,
 263 only CCBs such as, benidipine HCl or amlodipine besylate, showed potent
 264 anti-SARS-CoV-2 activity in vitro. The retrospective clinical investigation of 90
 265 COVID-19 patients with hypertension further revealed the beneficial effect of
 266 amlodipine besylate administration with reduced CFR (6.8%, n=44). In contrast,
 267 patients received ARBs/ACEIs/-blockers/thiazide as anti-hypertension drugs had the
 268 CFR of 41.2% (n=17) and the general CFR of this group of patient is 16.7% (n=90).
 269 These results together suggest that CCBs, such as amlodipine besylate, may be more
 270 effective drug options for treating COVID-19 patients who have hypertension as the

271 comorbidity.

272

273 The therapeutic mechanism of CCBs against COVID-19 still awaits further
 274 investigation. Several pathogenic viruses, such as Zika virus, dengue virus, H5N1
 275 avian influenza virus, etc, induce intracellular calcium influx to facilitate virus
 276 infection (23, 24). The elevated intracellular calcium level is associated with
 277 pathogenesis mechanisms including induction of mitochondrial dysfunction and cell
 278 death which will result in triggering of strong inflammatory responses (25-27).
 279 Consistently, CCBs were reported to have anti-inflammatory efficacy through
 280 regulating intracellular calcium level in patients and to decrease mortality in septic
 281 animal models with excessive inflammatory responses (28, 29). Particularly,
 282 amlodipine besylate has been shown to decrease levels of inflammatory markers and
 283 oxidative stress compared to baseline in patients with hypertension (30). Excessive
 284 inflammatory responses are reported to be associated with COVID-19 fatal outcome
 285 (11). It is possible that, besides inhibiting virus replication, CCBs may also function
 286 through alleviating inflammatory responses in the patients to achieve the clinical
 287 benefits in a synergistic way with its anti-viral efficacy.

288

289 Recently, CCBs have been reported to inhibit replication of several emerging viruses
 290 including Ebola virus, Marburg virus (31, 32), Junin virus(14), and severe fever with
 291 thrombocytopenia syndrome virus (SFTSV) (33). Particularly, CCB treatment was
 292 reported to be associated with reduced CFR among SFTS patients (13). Here we show

293 that, similar with SFTSV, CCBs inhibit the post-entry events of SARS-CoV-2
 294 replication. Although the exact inhibition mechanism still needs further investigation,
 295 it is possible that CCBs block the virus-induced intracellular calcium influx and
 296 impair calcium dependent cellular pathways that are critical for virus replication. This
 297 way CCBs may function as a host-oriented drug that inhibits virus replication through
 298 regulating virus-dependent host machinery and the chance for occurrence of resistant
 299 mutants is lower compared to anti-viral drugs that target specific virus constituents
 300 (34). This would be highly valuable for developing drugs against RNA viruses such as
 301 SARS-CoV-2 as these viruses generally have a high mutation rate.

302
 303 CQ has been shown to efficiently block SARS-CoV-2 entry in vitro and emerging
 304 evidences showed that administration of CQ has beneficial effects for COVID-19
 305 patients in clinics. It was also reported that administration of CQ can reduce overall
 306 inflammation in several conditions with little toxicity (9). Whether CQ also alleviates
 307 the excessive inflammatory responses in COVID-19 patients is currently unknown.
 308 Nevertheless, the significantly enhanced anti-SARS-CoV-2 efficacy upon combined
 309 application of CQ and CCB indicates that dual administration of these two drugs may
 310 achieve a more pronounced therapeutic effect. Several clinical trials are currently
 311 ongoing for analyzing the therapeutic effect of CQ in COVID-19 patients. Whether
 312 there are patients that have received combined drug treatment of CQ and CCB would
 313 be interesting for evaluation.

314

315 Results from this study suggested that CCB amlodipine besylate is associated with
 316 reduced case fatality rate of COVID-19 patients with hypertension. COVID-19
 317 patients with several comorbidities besides hypertension may have a more
 318 complicated underlying condition, and therefore was not included in the current study.
 319 Thus the therapeutic potential may only be applicable to the patients with
 320 hypertension as the only comorbidity. Evaluation with a larger patient cohort would
 321 further verify the potential therapeutic effect of the CCB. Additionally, dosing,
 322 side-effects and drug-drug interactions of the CCBs, similar with any drug that is in
 323 clinical use or testing, should be rigorously evaluated before clinical benefits can be
 324 more formally concluded.

325 **Materials and Methods**

326 **Cells, virus and reagents**

327 Vero E6 cell line was obtained from American Type Culture Collection (ATCC) and
328 maintained in minimum Eagle's medium (MEM; Gibco Invitrogen) supplemented
329 with 10% fetal bovine serum (FBS; Gibco Invitrogen), 1% antibiotic/antimycotic
330 (Gibco Invitrogen), at 37 °C in a humidified 5% CO₂ incubator. Huh7 cell line was
331 cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco Invitrogen)
332 supplemented with 10% FBS, 1% antibiotic/antimycotic (Gibco Invitrogen), at 37 °C
333 in a humidified 5% CO₂ incubator.

334
335 SARS-CoV-2 (nCoV-2019BetaCoV/Wuhan/WIV04/2019) was propagated in Vero E6
336 cells (2), and viral titer was determined by 50% tissue culture infective dose (TCID₅₀)
337 as described in our previous study(5). All the infection experiments were performed in
338 a biosafety level-3 (BLS-3) laboratory.

339
340 Benidipine HCl (Selleck Chemicals, no. S2017), Amlodipine besylate (Selleck
341 Chemicals, S1813), Cilnidipine (Selleck Chemicals, S1293), Nicardipine HCl
342 (Selleck Chemicals, S4181), Nifedipine (Selleck Chemicals, S1808), Isradipine
343 (Selleck Chemicals, S1662), Nimodipine (Selleck Chemicals, S1747), Nisoldipine
344 (Selleck Chemicals, S1748), Felodipine (Selleck Chemicals, S1885), 2-Aminoethyl
345 Diphenylborinate (2APB, Selleck Chemicals, S6657), BAPTA-AM (Selleck
346 Chemicals, S7534) and Chloroquine (Sigma-Aldrich, no.C6628) were purchased from

347 indicated companies.

348

349 **Evaluation of the antiviral activities of the test compounds**

350 Vero E6 pre-seeded in 48-well dish (1×10^5 cells/well) were treated with the different
351 concentration of the indicated compounds for 1 hour and infected with SARS-CoV-2
352 at an MOI of 0.05. Two hours later, the virus-drug mixture was removed and cells
353 were cultured with drug containing medium. At 24 hours p.i., the cell supernatant was
354 collected and lysed. The viral RNA extraction and quantitative real time PCR
355 (RT-PCR) analysis was described in our previous study (5).

356

357 **Evaluation of the cytotoxicity of the test compounds**

358 Vero E6 pre-seeded in 96-well dish (5×10^4 cells/well) were treated with the different
359 concentration of the indicated compounds, and 24 hours later, the relative numbers of
360 surviving cells were measured with cell counting kit-8 (GK10001, GLP BIO)
361 according to the manufacturer's instructions.

362

363 **Immunofluorescence microscopy**

364 To detect intracellular expression level of viral NP, cells were fixed with 4%
365 paraformaldehyde in advance. Fixed cells were permeabilized with 0.5% Triton
366 X-100 and blocked with 5% bovine serum albumin (BSA). Then they were incubated
367 for 2 hours with the anti-sera (1:1000 dilution) against the NP of a bat SARS-related
368 CoV as the primary antibody, followed by incubation with Alexa 488-labeled goat

369 anti-rabbit IgG (Abcam, ab150077; 1:500 dilution). The nuclei were stained with
370 DAPI (Sigma-Aldrich, no.D9542). The images were taken by a fluorescence
371 microscopy.

372

373 **Western blot analysis**

374 For Western blot analysis, proteins were separated by 12% SDS-PAGE and then
375 transferred onto PVDF membranes (Millipore). The membranes were blocked with 5%
376 BSA in TBST (TBS buffer with 0.1% Tween 20) for 1 hour at room temperature.
377 After washed with TBST for three times, the membranes were incubated with the
378 anti-NP sera (1:2000 dilution) overnight at 4°C. After washed with TBST for three
379 times, the membranes were incubated with horseradish peroxidase (HRP)-conjugated
380 Goat Anti-Rabbit IgG (Proteintech, China; 1:10000 dilution). Protein bands were
381 detected by SuperSignal West Pico Chemiluminescent substrate (Pierce).

382

383 **Clinical investigation**

384 **Study design and patients**

385 To investigate the clinical effect of amlodipine treatment on COVID-19, we
386 conducted a retrospective clinical investigation on the patients who were admitted to
387 the Tongji Hospital, Union Hospital, which are the major tertiary teaching hospitals in
388 Wuhan, China, and are responsible for the treatments of severe COVID-19 cases. The
389 diagnosis of COVID-19 was made based on the World Health Organization interim
390 guidance, and the confirmed cases denoted the patients whose nasal or pharyngeal

391 swab samples were positive for real-time reverse-transcription
392 polymerase-chain-reaction (RT-PCR) assay. Adult confirmed patients were checked
393 for medical record of comorbidities and related therapeutic drugs by a trained research
394 medical staff, and the COVID-19 patients who had hypertension were recruited into
395 the study. Patients, who had other comorbidities, such as coronary heart diseases,
396 cerebral infarction, diabetes, chronic obstructive pulmonary disease, pulmonary
397 tuberculosis, chronic kidney disease, and malignancy, were excluded. The research
398 protocol was approved by the human ethics committee of the hospital in accordance
399 with the medical research regulations of China (TJ-IRB20200102), and oral informed
400 consents were obtained from all patients or patients' family members.

401 **Data collection**

402 Data about demography, clinical manifestations, and laboratory testing results were
403 retrospectively collected by reviewing medical records and entered into standardized
404 database. Medication use during hospitalization including information on
405 antihypertensive drugs (i.e. calcium channel blockers, angiotensin receptor blockers,
406 and diuretics) was also recorded. Serial throat swabs were collected for the testing of
407 HCoV-19 RNA with the use of RT-PCR during the patients' hospitalization.

408 **Outcome**

409 The primary outcome was case fatality.

410 **Statistics**

411 Continuous variables were summarized as means and standard deviations or as
412 medians and interquartile-range (IQR). Student's *t* test or nonparametric test

413 (Mann-Whitney test) was used as appropriate for comparisons of continuous variables
 414 between two groups, and ANOVA test or nonparametric test was used as appropriate
 415 for comparisons of continuous variables among multiple groups. Categorical variables
 416 were summarized as frequencies and proportions, and were analysed by Chi-square
 417 test or Fisher's exact test as appropriate. We used the Kaplan-Meier method and the
 418 log-rank test to analyse time-to-event data for treatment effect analysis. We calculated
 419 HRs and 95% CI by using Cox regression models. A 2-sided *P* value of <0.05 was
 420 considered to be statistically significant. All statistical analyses were performed using
 421 SPSS software, version 19.0.

422 **Acknowledgements**

423 We thank Hao Tang, Jia Wu, Jun Liu and Tao Du from BSL-3 Laboratory of Wuhan
424 Institute of Virology for their critical support.

425 **Funding**

426 The study was supported by the Natural Science Foundation of China (31970165,
427 81825019, 81722041, 31770188), the Strategic Priority Research Program of the
428 Chinese Academy of Sciences (XDB29010204), National Science and Technology
429 Major Project (No. 2018ZX10101004001005), and the Hubei Science and Technology
430 Project (2020FCA003).

431 **Author contributions:**

432 L.-K.Z., K.P., and G.X. conceived and supervised the study. K.P., L.-K.Z., H.L., and
433 G.X. wrote the manuscript. H.Z. collected clinical data. H.L., W.L., H.Z. and H.C.
434 analyzed clinical data. Y.S., X.-M.J., W.-J.S., Y.W., S.L., and Y.-L.Z. performed in
435 vitro experiment. L.-K.Z., K.P., Y.S., and H.L contributed to the design of the study
436 and data analysis. All authors had access to the study data, and reviewed and approved
437 the final manuscript.

438 **Competing interest:** No conflicts of interest declared.

439 Reference

- 440 1. N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P.
441 Niu, F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G. F. Gao, W. Tan, I. China Novel Coronavirus,
442 T. Research, A Novel Coronavirus from Patients with Pneumonia in China, 2019. *The New*
443 *England journal of medicine*, (2020); published online EpubJan 24
444 (10.1056/NEJMoa2001017).
- 445 2. P. Zhou, X. L. Yang, X. G. Wang, B. Hu, L. Zhang, W. Zhang, H. R. Si, Y. Zhu, B. Li, C. L.
446 Huang, H. D. Chen, J. Chen, Y. Luo, H. Guo, R. D. Jiang, M. Q. Liu, Y. Chen, X. R. Shen, X.
447 Wang, X. S. Zheng, K. Zhao, Q. J. Chen, F. Deng, L. L. Liu, B. Yan, F. X. Zhan, Y. Y. Wang,
448 G. F. Xiao, Z. L. Shi, A pneumonia outbreak associated with a new coronavirus of probable
449 bat origin. *Nature*, (2020); published online EpubFeb 3 (10.1038/s41586-020-2012-7).
- 450 3. C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T.
451 Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G.
452 Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with
453 2019 novel coronavirus in Wuhan, China. *The Lancet*,
454 (2020)10.1016/s0140-6736(20)30183-5).
- 455 4. G. Li, E. De Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nature*
456 *reviews. Drug discovery* **19**, 149-150 (2020); published online EpubMar
457 (10.1038/d41573-020-00016-0).
- 458 5. M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong, G. Xiao,
459 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus
460 (2019-nCoV) in vitro. *Cell Research*, (2020)10.1038/s41422-020-0282-0).
- 461 6. T. K. Warren, R. Jordan, M. K. Lo, A. S. Ray, R. L. Mackman, V. Soloveva, D. Siegel, M.
462 Perron, R. Bannister, H. C. Hui, N. Larson, R. Strickley, J. Wells, K. S. Stuthman, S. A. Van
463 Tongeren, N. L. Garza, G. Donnelly, A. C. Shurtleff, C. J. Retterer, D. Gharaibeh, R. Zamani,
464 T. Kenny, B. P. Eaton, E. Grimes, L. S. Welch, L. Gomba, C. L. Wilhelmsen, D. K. Nichols, J.
465 E. Nuss, E. R. Nagle, J. R. Kugelman, G. Palacios, E. Doerffler, S. Neville, E. Carra, M. O.
466 Clarke, L. Zhang, W. Lew, B. Ross, Q. Wang, K. Chun, L. Wolfe, D. Babusis, Y. Park, K. M.
467 Stray, I. Trancheva, J. Y. Feng, O. Barauskas, Y. Xu, P. Wong, M. R. Braun, M. Flint, L. K.
468 McMullan, S. S. Chen, R. Fearn, S. Swaminathan, D. L. Mayers, C. F. Spiropoulou, W. A.
469 Lee, S. T. Nichol, T. Cihlar, S. Bavari, Therapeutic efficacy of the small molecule GS-5734
470 against Ebola virus in rhesus monkeys. *Nature* **531**, 381-385 (2016); published online
471 EpubMar 17 (10.1038/nature17180).
- 472 7. T. P. Sheahan, A. C. Sims, R. L. Graham, V. D. Menachery, L. E. Gralinski, J. B. Case, S. R.
473 Leist, K. Pyrc, J. Y. Feng, I. Trantcheva, R. Bannister, Y. Park, D. Babusis, M. O. Clarke, R. L.
474 Mackman, J. E. Spahn, C. A. Palmiotti, D. Siegel, A. S. Ray, T. Cihlar, R. Jordan, M. R.
475 Denison, R. S. Baric, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic
476 coronaviruses. *Science translational medicine* **9**, (2017); published online EpubJun 28
477 (10.1126/scitranslmed.aal3653).
- 478 8. T. P. Sheahan, A. C. Sims, S. R. Leist, A. Schafer, J. Won, A. J. Brown, S. A. Montgomery, A.
479 Hogg, D. Babusis, M. O. Clarke, J. E. Spahn, L. Bauer, S. Sellers, D. Porter, J. Y. Feng, T.
480 Cihlar, R. Jordan, M. R. Denison, R. S. Baric, Comparative therapeutic efficacy of remdesivir
481 and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nature*

- 482 *communications* **11**, 222 (2020); published online EpubJan 10 (10.1038/s41467-019-13940-6).
- 483 9. R. Thome, S. C. Lopes, F. T. Costa, L. Verinaud, Chloroquine: modes of action of an
484 undervalued drug. *Immunology letters* **153**, 50-57 (2013); published online EpubJun
485 (10.1016/j.imlet.2013.07.004).
- 486 10. J. Gao, Z. Tian, X. Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy
487 in treatment of COVID-19 associated pneumonia in clinical studies. *Bioscience trends* **14**,
488 72-73 (2020); published online EpubMar 16 (10.5582/bst.2020.01047).
- 489 11. F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X. Gu, L. Guan, Y.
490 Wei, H. Li, X. Wu, J. Xu, S. Tu, Y. Zhang, H. Chen, B. Cao, Clinical course and risk factors
491 for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
492 *Lancet*, (2020); published online EpubMar 11 (10.1016/S0140-6736(20)30566-3).
- 493 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
494 Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
495 Calcium Channel Blockers. [Updated 2017 Jan 11].
- 496 13. H. Li, L.-K. Zhang, S.-F. Li, S.-F. Zhang, W.-W. Wan, Y.-L. Zhang, Q.-L. Xin, K. Dai, Y.-Y.
497 Hu, Z.-B. Wang, X.-T. Zhu, Y.-J. Fang, N. Cui, P.-H. Zhang, C. Yuan, Q.-B. Lu, J.-Y. Bai, F.
498 Deng, G.-F. Xiao, W. Liu, K. Peng, Calcium channel blockers reduce severe fever with
499 thrombocytopenia syndrome virus (SFTSV) related fatality. *Cell Research*,
500 (2019)10.1038/s41422-019-0214-z).
- 501 14. M. Lavanya, C. D. Cuevas, M. Thomas, S. Cherry, S. R. Ross, siRNA screen for genes that
502 affect Junin virus entry uncovers voltage-gated calcium channels as a therapeutic target.
503 *Science translational medicine* **5**, 204ra131 (2013); published online EpubSep 25
504 (5/204/204ra131 [pii] 10.1126/scitranslmed.3006827).
- 505 15. S. Wang, Y. Liu, J. Guo, P. Wang, L. Zhang, G. Xiao, W. Wang, Screening of FDA-Approved
506 Drugs for Inhibitors against Japanese Encephalitis Virus Infection. *J Virol*, (2017); published
507 online EpubAug 16 (10.1128/JVI.01055-17).
- 508 16. D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, B. Wang, H. Xiang, Z. Cheng, Y. Xiong, Y.
509 Zhao, Y. Li, X. Wang, Z. Peng, Clinical Characteristics of 138 Hospitalized Patients With
510 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Jama*, (2020); published
511 online EpubFeb 7 (10.1001/jama.2020.1585).
- 512 17. L. Missiaen, G. Callewaert, H. De Smedt, J. B. Parys, 2-Aminoethoxydiphenyl borate affects
513 the inositol 1,4,5-trisphosphate receptor, the intracellular Ca²⁺ pump and the non-specific
514 Ca²⁺ leak from the non-mitochondrial Ca²⁺ stores in permeabilized A7r5 cells. *Cell calcium*
515 **29**, 111-116 (2001); published online EpubFeb (10.1054/ceca.2000.0163).
- 516 18. P. K. Whelton, R. M. Carey, W. S. Aronow, D. E. Casey, Jr., K. J. Collins, C. Dennison
517 Himmelfarb, S. M. DePalma, S. Gidding, K. A. Jamerson, D. W. Jones, E. J. MacLaughlin, P.
518 Muntner, B. Ovbiagele, S. C. Smith, Jr., C. C. Spencer, R. S. Stafford, S. J. Taler, R. J. Thomas,
519 K. A. Williams, Sr., J. D. Williamson, J. T. Wright, Jr., 2017
520 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
521 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults:
522 Executive Summary: A Report of the American College of Cardiology/American Heart
523 Association Task Force on Clinical Practice Guidelines. *Circulation* **138**, e426-e483 (2018);
524 published online EpubOct 23 (10.1161/CIR.0000000000000597).
- 525 19. T. Novel Coronavirus Pneumonia Emergency Response Epidemiology, [The epidemiological

- characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China].
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi **41**, 145-151 (2020);
published online EpubFeb 17 (10.3760/cma.j.issn.0254-6450.2020.02.003).
20. Y. Ishiyama, P. E. Gallagher, D. B. Averill, E. A. Tallant, K. B. Brosnihan, C. M. Ferrario,
Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of
angiotensin II receptors. *Hypertension* **43**, 970-976 (2004); published online EpubMay
(10.1161/01.HYP.0000124667.34652.1a).
21. R. M. Carey, Angiotensin type-1 receptor blockade increases ACE 2 expression in the heart.
Hypertension **43**, 943-944 (2004); published online EpubMay
(10.1161/01.HYP.0000124669.02394.72).
22. L. Fang, G. Karakiulakis, M. Roth, Are patients with hypertension and diabetes mellitus at
increased risk for COVID-19 infection? *The Lancet Respiratory Medicine*,
(2020)10.1016/s2213-2600(20)30116-8).
23. P. Donate-Macian, J. Jungfleisch, G. Perez-Vilaro, F. Rubio-Moscardo, A. Peralvarez-Marin, J.
Diez, M. A. Valverde, The TRPV4 channel links calcium influx to DDX3X activity and viral
infectivity. *Nature communications* **9**, 2307 (2018); published online EpubJun 13
(10.1038/s41467-018-04776-7).
24. M. Ueda, T. Daidoji, A. Du, C. S. Yang, M. S. Ibrahim, K. Ikuta, T. Nakaya, Highly
pathogenic H5N1 avian influenza virus induces extracellular Ca²⁺ influx, leading to apoptosis
in avian cells. *Journal of virology* **84**, 3068-3078 (2010); published online EpubMar
(10.1128/JVI.01923-09).
25. J. R. Yaron, S. Gangaraju, M. Y. Rao, X. Kong, L. Zhang, F. Su, Y. Tian, H. L. Glenn, D. R.
Meldrum, K(+) regulates Ca(2+) to drive inflammasome signaling: dynamic visualization of
ion flux in live cells. *Cell death & disease* **6**, e1954 (2015); published online EpubOct 29
(10.1038/cddis.2015.277).
26. T. Horng, Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3
inflammasome. *Trends in immunology* **35**, 253-261 (2014); published online EpubJun
(10.1016/j.it.2014.02.007).
27. P. Maher, K. van Leyen, P. N. Dey, B. Honrath, A. Dolga, A. Methner, The role of Ca(2+) in
cell death caused by oxidative glutamate toxicity and ferroptosis. *Cell calcium* **70**, 47-55
(2018); published online EpubMar (10.1016/j.ceca.2017.05.007).
28. I. V. G. Silva, R. C. de Figueiredo, D. R. A. Rios, Effect of Different Classes of
Antihypertensive Drugs on Endothelial Function and Inflammation. *International journal of
molecular sciences* **20**, (2019); published online EpubJul 14 (10.3390/ijms20143458).
29. J. A. D'Elia, L. A. Weinrauch, Calcium Ion Channels: Roles in Infection and Sepsis
Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk
for Infection. *International journal of molecular sciences* **19**, (2018); published online
EpubAug 21 (10.3390/ijms19092465).
30. H. J. Kim, S. J. Han, D. J. Kim, H. C. Jang, S. Lim, S. H. Choi, Y. H. Kim, D. H. Shin, S. H.
Kim, T. H. Kim, Y. B. Ahn, S. H. Ko, N. H. Kim, J. A. Seo, H. Y. Kim, K. W. Lee, Effects of
valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a
randomized, multicenter study. *The Korean journal of internal medicine* **32**, 497-504 (2017);
published online EpubMay (10.3904/kjim.2015.404).
31. L. M. Johansen, L. E. DeWald, C. J. Shoemaker, B. G. Hoffstrom, C. M. Lear-Rooney, A.

- 570 Stossel, E. Nelson, S. E. Delos, J. A. Simmons, J. M. Grenier, L. T. Pierce, H. Pajouhesh, J.
571 Lehar, L. E. Hensley, P. J. Glass, J. M. White, G. G. Olinger, A screen of approved drugs and
572 molecular probes identifies therapeutics with anti-Ebola virus activity. *Science translational*
573 *medicine* **7**, 290ra289 (2015); published online EpubJun 03 (10.1126/scitranslmed.aaa5597).
- 574 32. L. E. DeWald, J. Dyall, J. M. Sword, L. Torzewski, H. Zhou, E. Postnikova, E. Kollins, I.
575 Alexander, R. Gross, Y. Cong, D. M. Gerhardt, R. F. Johnson, G. G. Olinger, Jr., M. R.
576 Holbrook, L. E. Hensley, P. B. Jahrling, The Calcium Channel Blocker Bepridil Demonstrates
577 Efficacy in the Murine Model of Marburg Virus Disease. *The Journal of infectious diseases*,
578 (2018); published online EpubJul 4 (10.1093/infdis/jiy332).
- 579 33. H. Li, L. K. Zhang, S. F. Li, S. F. Zhang, W. W. Wan, Y. L. Zhang, Q. L. Xin, K. Dai, Y. Y. Hu,
580 Z. B. Wang, X. T. Zhu, Y. J. Fang, N. Cui, P. H. Zhang, C. Yuan, Q. B. Lu, J. Y. Bai, F. Deng,
581 G. F. Xiao, W. Liu, K. Peng, Calcium channel blockers reduce severe fever with
582 thrombocytopenia syndrome virus (SFTSV) related fatality. *Cell research* **29**, 739-753 (2019);
583 published online EpubSep (10.1038/s41422-019-0214-z).
- 584 34. S. M. Heaton, Harnessing host-virus evolution in antiviral therapy and immunotherapy.
585 *Clinical & translational immunology* **8**, e1067 (2019)10.1002/cti2.1067).

586

Figure legends

Figure 1. Evaluation of anti-SARS-CoV-2 activity of a panel of CCBs.

Vero E6 cells were treated with indicated concentrations of compounds and infected with SARS-CoV-2 at an MOI of 0.05, and at 24 hours p.i., supernatant was collected and cells were fixed. Chloroquine (CQ, 5 μ M) was used as positive control. (A) Viral copy number in the supernatant was measured with quantitative RT-PCR; (B) intracellular NP level in cells treated with 30 μ M indicated compound was monitored with immunofluorescence. The experiments were done in triplicates, and data shown are means $\pm$ SD. Bars: 400 μ m.

Figure 2. Dose dependent effects of benidipine HCl, amlodipine besylate, cilnidipine, nicardipine HCl, BAPTA-AM and 2ABP on SARS-CoV-2 replication. Vero E6 cells were treated with indicated concentrations of compounds and infected with SARS-CoV-2 at an MOI of 0.05, and at 24 hours p.i., supernatant was collected and viral copy number in the supernatant was measured with quantitative RT-PCR. Cell viability was measured with CCK8 assay. The left Y-axis of the graph indicates mean % inhibition of virus, while right Y-axis represents mean % cell viability. The experiments were done in triplicates, and data shown are means $\pm$ SD. The IC_{50} and CC_{50} values were calculated by Graphpad Prism 6.0.

606

Figure 3. Time-of-addition experiment of benidipine HCl and 2ABP.

(A) For “Full-time” treatment, Vero E6 cells were pre-treated with compounds for 1 hour, and then infected with virus. At 2 hours p.i., the supernatant was removed, and the cells were cultured with compound-containing medium until the end of the experiment. For “Entry” treatment, Vero E6 cells were pre-treated with compounds for 1 hour, and then infected with virus. At 2 hours p.i., the supernatant was removed, and the cells were cultured with fresh culture medium until the end of the experiment. For “Post-entry” experiment, Vero E6 cells were infected with virus, and at 2 hours p.i., cells were treated with compound-containing medium until the end of the experiment. For all these experiments, Vero E6 cells were infected with SARS-CoV-2 at an MOI of 0.05, and virus copy number in the supernatant was quantified by quantitative RT-PCR (B) and NP expression in infected cells was analyzed by western blot (C) and immunofluorescence with NP antibody (D) at 24 hours p.i.. The Y-axis of the graph represents mean % inhibition of virus. The experiments were performed in triplicates.

623 **Figure 4. Effect of drug treatment with two ACEIs (enalaprilat dihydrate,**
624 **enalapril maleate) or two ARBs (losartan potassium, valsartan) on SARS-CoV-2**
625 **replication in vitro.**
626 Vero E6 cells were treated with indicated concentrations of compounds and infected
627 with SARS-CoV-2 at an MOI of 0.05. At 24 hours p.i., supernatant was collected and
628 viral copy number in the supernatant was measured with quantitative RT-PCR. Cell
629 viability was measured with CCK8 assay. The left Y-axis of the graph indicates mean %
630 inhibition of virus, while right Y-axis represents mean % cell viability. The
631 experiments were performed in triplicates, and data shown are means $\pm$ SD.

632

Figure 5. The antiviral activities of chloroquine (CQ) and/or benidipine HCl against SARS-CoV-2 replication.

Vero E6 cells were treated with indicated concentrations of compounds separately or in combination and infected with SARS-CoV-2 at an MOI of 0.05. At 24 hours p.i., supernatant was collected and viral copy number in the supernatant was measured with quantitative RT-PCR (A), and NP expression in infected cells was analyzed by immunofluorescence with NP antibody (B). The experiments were performed in triplicates, and data shown are means $\pm$ SD. Comparison of mean values between two groups was analyzed by the student's t test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. Bars: 400 μ m.

644 **Figure 6. Analysis of amlodipine besylate treatment on probability of survival in**

645 **COVID-19 patients with hypertension.**

646 Treatment effect on probability of survival of amlodipine besylate treated patients was
 647 compared with non-amlodipine besylate treated patients (A), or with patients received
 648 different types of anti-hypertension drugs (B). Other antihypertensive drugs include
 649 angiotensin receptor blockers, angiotensin converting enzyme inhibitors, β -blockers,
 650 and thiazide. The Kaplan-Meier method was used to analyze the time-to-event data.

651

652 **Table 1. Treatment effect of amlodipine besylate and other antihypertensive drugs in reducing mortality in the patients of COVID-19.**

	Total (n=90)	Survival (n=75)	Fatal (n=15)	<i>P</i> ^a	HR (95% CI)	<i>P</i> ^b	Adjusted HR (95% CI)	<i>P</i> ^c
Treatment regimen								
No treatment	9	7 (77.8)	2 (22.2)	0.026	Reference		Reference	
Amlodipine besylate	44	41 (93.2)	3 (6.8)		0.141 (0.036-0.546)	0.005	0.086 (0.014-0.551)	0.010
Nifedipine	16	14 (87.5)	2 (12.5)		0.243 (0.050-1.174)	0.078	0.213 (0.040-1.135)	0.070
Other CCBs	4	3 (75.0)	1 (25.0)		0.483 (0.100-2.329)	0.365	0.634 (0.104-3.853)	0.621
Other antihypertensive drugs	17	10 (58.8)	7 (41.2)		0.470 (0.058-3.834)	0.480	0.727 (0.078-6.792)	0.780
Amlodipine besylate								
No	44	41 (93.2)	3 (6.8)	0.022	Reference		Reference	
Yes	46	34 (73.9)	12 (26.1)		0.253 (0.071-0.895)	0.033	0.182 (0.037-0.897)	0.036

653 Other antihypertensive drugs include angiotensin receptor blockers, angiotensin converting enzyme inhibitors, β -blockers, and thiazide.

654 ^aAnalysed by Chi-square test or Fisher's exact test.

655 ^bAnalysed by Kaplan-Meier model

656 ^cAnalysed by Cox regression model by adjusting for age, sex, the delay from symptom onset to hospital admission, and therapies administration.